Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:

• Introduction (0:00)
• Preventing Ovarian Cancer (1:04)
• Endometrial Cancer (5:27)
• Ovarian Cancer (25:36)
• Cervical Cancer (54:04)

CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics:

• Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)
• Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)
• Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)
• Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)

CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics:

• Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)
• A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)
• Current and future role of avutometinib with defactinib for LGSOC (19:23)
• A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)
• Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)

CME information and select publications

Featuring an interview with Dr Ramez Eskander, including the following topics:

• Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)
• Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)
• Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)
• Current and investigational targets of ADCs in gynecologic cancers (17:14)
• Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)
• Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)
• Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)
• Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)
• Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)

CME information and select publications

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:

• Introduction (00:00)
• Overview of Ovarian Cancer (OC) (2:12)
• Role of PARP Inhibitors in Advanced OC (4:56)
• Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
• Role of Relacorilant in Advanced OC (57:08)
• Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Introduction (00:00)
• Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
• Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
• Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

• Introduction (00:00)
• Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
• Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
• Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
• Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
• Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)
• Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)

CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:

• Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)
• Molecular analyses in the assessment and management of endometrial cancer (07:33)

CME information and select publications